



ASX ANNOUNCEMENT

23 JANUARY 2023

SUCCESSFUL COMPLETION OF 28-DAY FOLLOW UP PERIOD FOR 3RD PATIENT COHORT IN BRAIN CANCER PHASE 1 TRIAL

- 3rd dose cohort in the CHM 1101 (CLTX CAR T) cell therapy phase 1 clinical trial completed
- All patients have advanced past the 28-day safety follow up period without experiencing any dose limiting toxicities
- This 3rd dose cohort treated patients at a total dose of 240×10^6 CHM 1101 (CLTX CAR T) cells through dual routes of administration
- The phase 1 clinical trial will now advance to the 4th and final dose cohort with dual routes of administration at a total dose of 440×10^6 CHM 1101 (CLTX CAR T) cells

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company and an Australian leader in cell therapy, is pleased to provide an update to 22 December 2022 announcement and confirm that all patients dosed in the 3rd patient cohort in City of Hope National Medical Center’s phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial have now advanced beyond the 28-day follow up period without experiencing dose-limiting toxicities.

Patients in the 3rd dose cohort received a total dose of 240×10^6 CHM 1101 (CLTX CAR T) cells through dual routes of intratumoral (ICT) and intraventricular (ICV) administration.

Achievement of this milestone enables the trial to advance to the 4th and final dose cohort wherein subjects will be treated with a total dose of 440×10^6 CHM 1101 CAR T cells by ICT and ICV administration.

City of Hope, one of the largest cancer research and treatment organizations in the United States, initiated and is leading the current Phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial. Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the chlorotoxin CAR-T cells from City of Hope.

The Phase 1A study aims to enroll 18-36 patients with MMP2+ recurrent or progressive GBM across four dose levels. Study objectives are to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a phase 2 trial.

For personal use only



ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. Additional work is being undertaken to expand CLTX to additional solid tumours, beginning with metastatic melanoma.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

For personal use only



CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

For personal use only